Immunological monitoring of residual disease in treated thymic acute lymphoblastic leukaemia.
D000293:Adolescent; D000328:Adult; D000951:Antigens, Neoplasm / Q000032:analysis; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001853:Bone Marrow / Q000187:drug effects / Q000276:immunology / Q000473:pathology*; D002648:Child; D002675:Child, Preschool; D005260:Female; D005455:Fluorescent Antibody Technique; D005500:Follow-Up Studies; D006801:Humans; D007945:Leukemia, Lymphoid / Q000188:drug therapy / Q000276:immunology* / Q000473:pathology; D008297:Male; D010641:Phenotype; D013601:T-Lymphocytes / Q000276:immunology* / Q000473:pathology; D013997:Time Factors
D000951:Antigens, Neoplasm; D000970:Antineoplastic Agents